Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9333495 | 1.00 | MEN1 (0.55) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9333522 | 1.00 | MEN1 (0.55) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL28912718 | 1.00 | MEN1 (0.55) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9181812 | 0.92 | TSHR (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL3150626 | 0.92 | TSHR (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL17450348 | 0.91 | DGKA (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL6739583 | 0.87 | NAAA (0.61) | NAAADGKAEPHX1TSHRALDH1A1 | |
| SCHEMBL1206999 | 0.87 | NAAA (0.61) | NAAADGKAEPHX1TSHRALDH1A1 | |
| SCHEMBL7129437 | 0.87 | NAAA (0.61) | NAAADGKAEPHX1TSHRALDH1A1 | |
| SCHEMBL11131653 | 0.87 | NAAA (0.61) | NAAADGKAEPHX1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | JAMES KENNETH D | 2010-08-26 | — | — | US | disclosed |
| EP-1569683-B1 | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | BIOCON LTD (IN) | 2010-03-03 | — | — | EP | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7662773-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-02-16 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-7648962-B2 | which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure | BIOCON LIMITED (IN) | 2010-01-19 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| US-20080207505-A1 | Bna Conjugates and Methods of Use | JAMES KENNETH D | 2008-08-28 | — | — | US | disclosed |
| WO-2006076471-A2 | BNP CONJUGATES AND METHODS OF USE | NOBEX CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005116655-A2 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2004047871-A2 | MODIFIED NATURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NOBEX CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207505-A1 | Bna Conjugates and Methods of Use | NPR1, NPPA, NPR3 | MEN1 2236/4885THRB 1460/4885HTT 2112/4885 |
| US-20100216714-A1 | NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF | NPR1, NPPA, NPR3 | MEN1 1726/4885THRB 1101/4885HTT 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.